CompletedPhase 4

Combined Vaginal Misoprostol and Perivascular Vasopressin

United States74 participantsStarted 2017-04-26

Plain-language summary

Injection of Vasopressin into the uterine tissue surrounding fibroids constricts blood vessels, and has been found to be beneficial by decreasing blood flow to fibroids, and thereby resulting in less bleeding with removal. Additionally, Misoprostol has been looked at as an additional method to decrease operative blood loss given its ability to increase uterine muscle tone, which therefore constricts the amount of blood flow to the uterus.

Who can participate

Age range18 Years – 55 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. History of adverse reaction or allergy to Vasopressin.
✕. History of adverse reaction or allergy to Misoprostol.
✕. Medical contraindication to use of Vasopressin or Misoprostol
✕. Suspicion of possible reproductive cancer with contraindication of morcellation of uterine tissue.
✕. Significant medical condition or laboratory result that in the opinion of the Investigator indicate an increased vulnerability to study subject which exposes the subject to an unreasonable risk as a result of participating.
✕. Any clinically significant even or condition uncovered during the surgery, such as excessive bleeding or decompensation, that might render the subject medically unstable to continue the study or complicate the subject's intraoperative or postoperative course.
✕. Pregnant women

What they're measuring

Hemoglobin Levels Difference Between Pre and Post Surgery.

Timeframe: 1 hour

Trial details

NCT IDNCT03815344

SponsorAntonios Likourezos

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-06-30

Results submitted2019-12-11

View on ClinicalTrials.gov More Leiomyoma trials